Physician profile
Nitin Kumar Gupta
NPI 1568620003
$3,244.26
in general payments reported to CMS, 2019-2025
26 companies · $982 in 2025
The $982 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $260 · 2021: $41.12 · 2022: $327 · 2023: $205 · 2024: $694 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $400.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $374.09 | 2024-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.15 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $336.89 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $273.01 | 2020-2025 | Brilinta, Farxiga, Wainua |
| Abbott Laboratories | $243.84 | 2019-2022 | |
| Amgen INC. | $163.01 | 2019-2025 | Repatha, Tezspire, Repatha |
| Lexicon Pharmaceuticals, INC. | $137.89 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $133.61 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $128.02 | 2019-2020 | |
| Boston Scientific Corporation | $110.06 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $91.95 | 2019 | |
| Scpharmaceuticals INC. | $81.07 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $76.79 | 2019-2025 | Eylea Hd |
| Pfizer INC. | $62.39 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $50.36 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $48.37 | 2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $31.22 | 2025 | Wegovy |
| Amarin Pharma, INC. | $30.17 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $29.07 | 2020 | |
| Sanofi Pasteur INC. | $24.57 | 2019 | |
| Esperion Therapeutics, INC. | $16.77 | 2024 | Nexletol |
| Chiesi USA, INC. | $16.39 | 2019 | |
| Teleflex LLC | $16.28 | 2023 | Guideliner |
| Edwards Lifesciences Corporation | $14.58 | 2019 | |
| Bardy Diagnostics, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.